Cagrilintide is dosed at 250 mcg–2.4 mg weekly by subcutaneous injection in educational protocols, starting low and titrating upward. A 10 mg blend reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.
Cagrilintide + Semaglutide is a dual‑agonist combination blending an amylin analog (cagrilintide) with a GLP‑1 receptor agonist (Semaglutide). Clinical trials demonstrate superior weight reduction versus either agent alone, with the combination targeting complementary satiety pathways. This educational protocol presents a once‑weekly subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.
Educational guide for reconstitution and weekly dosing
| Week/Phase | Dose per Peptide (mcg / mg) | Units (mL) |
|---|---|---|
| Weeks 1–4 | 250 mcg (0.25 mg) each | 15 units (0.15 mL) |
| Weeks 5–8 | 500 mcg (0.50 mg) each | 30 units (0.30 mL) |
| Weeks 9–12 | 1000 mcg (1.0 mg) each | 60 units (0.60 mL) |
| Weeks 13–16 | 1700 mcg (1.7 mg) each | 102 units (1.02 mL) |
| Week 17+ | 2400 mcg (2.4 mg) each | 144 units (1.44 mL) |
Note: Each dose delivers equivalent amounts of both cagrilintide and Semaglutide (e.g., 0.25 mg cagrilintide + 0.25 mg Semaglutide at Week 1). The 2.4 mg target mirrors clinical trial protocols.
Reconstitution Math
Reconstitution Steps
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Plan based on an 8–16 week weekly protocol with gradual titration.
Concise summary of the once‑weekly regimen.
Suggested weekly titration approach.
Proper storage preserves peptide quality.
Practical considerations for consistency and safety.
Cagrilintide is a long‑acting amylin analog that reduces appetite via central satiety pathways, while Semaglutide activates GLP‑1 receptors to enhance glucose‑dependent insulin secretion and suppress glucagon. The combination leverages complementary mechanisms: amylin primarily delays gastric emptying and signals satiety through the area postrema, while GLP‑1 enhances pancreatic β‑cell function and central appetite suppression. Clinical trials of the co‑administered regimen (CagriSema) show greater body‑weight reduction than either agent alone.
Observations from clinical literature.
Complementary strategies for best outcomes.
General subcutaneous guidance from clinical best‑practice resources.
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
Explore related research dosage protocols and background reading for Cagrilintide + Semaglutide.